Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sercan Aksoy

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
Medicine|July 26, 2024
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerHasan Cagri Yildirim, Mustafa Buyukkor, Gözde Kavgaci, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Targeting LINC00152 activates cAMP/Ca<sup>2+</sup>/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerOzge Saatci, Rashed Alam, Kim-Tuyen Huynh-Dam, et al.
Scientific Reports|March 27, 2026
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective studyAhmet Oruç, İlknur Deliktaş Onur, Galip Can Uyar, et al.
Experimental Hematology & Oncology|June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerTaha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.
Cell Death & Disease|June 15, 2024
Targeting LINC00152 activates cAMP/Ca<sup>2+</sup>/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerOzge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, et al.
Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Oncology|February 9, 2013
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patientsDoğan Uncu, Sercan Aksoy, Bülent Çetin, et al.
Nature Communications|May 17, 2020
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancerOzge Saatci, Aysegul Kaymak, Umar Raza, et al.
Acta Oncologica (Stockholm, Sweden)|April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH studyAhmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
Medicine|July 26, 2024
The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancerHasan Cagri Yildirim, Mustafa Buyukkor, Gözde Kavgaci, et al.
Biorxiv : the Preprint Server for Biology|March 18, 2024
Targeting LINC00152 activates cAMP/Ca<sup>2+</sup>/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerOzge Saatci, Rashed Alam, Kim-Tuyen Huynh-Dam, et al.
Scientific Reports|March 27, 2026
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective studyAhmet Oruç, İlknur Deliktaş Onur, Galip Can Uyar, et al.
Experimental Hematology & Oncology|June 9, 2026
Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancerTaha Koray Sahin, Cemal Orhan, Ibrahim Hanifi Ozercan, et al.
Cell Death & Disease|June 15, 2024
Targeting LINC00152 activates cAMP/Ca<sup>2+</sup>/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerOzge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, et al.
Future Oncology (London, England)|June 4, 2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412Jean-Pascal Machiels, Yungan Tao, Barbara Burtness, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 12, 2026
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 StudyLisa Licitra, Makoto Tahara, Kevin Harrington, et al.
Oncology|February 9, 2013
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patientsDoğan Uncu, Sercan Aksoy, Bülent Çetin, et al.
Nature Communications|May 17, 2020
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancerOzge Saatci, Aysegul Kaymak, Umar Raza, et al.
Acta Oncologica (Stockholm, Sweden)|April 21, 2023
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH studyAhmet Bilici, Omer Fatih Olmez, Muhammed Ali Kaplan, et al.
Pageof 21